In a two-year placebo-controlled trial, repeated cortisone injections caused significantly more cartilage loss than saline. They gave no better pain relief at two years. Each shot trades cartilage you cannot replace for relief that does not last.
Maybe you have already sensed it. The cortisone shots are a holding pattern, not a solution. The relief keeps arriving on a shorter lease. And nobody has told you where this arrangement is supposed to end.
That instinct deserves respect. It also happens to be supported by the evidence.
Do repeated cortisone injections damage cartilage?
The data here is unusually clean, because the trial compared against a placebo, not against nothing.
In a rigorous two-year placebo-controlled trial, repeated cortisone injections caused significantly more cartilage loss than saline — and produced no better pain relief at two years.
Two findings, and the second is what makes the first so hard to argue around.
Suppose repeated cortisone had given clearly better pain control over two years. Then there would be a real trade-off to weigh: cartilage against comfort. That would be a fair clinical judgment call, with good arguments on both sides. That is not what the trial showed. It showed more cartilage lost, and no better relief at the two-year mark.
What is the downside of getting cortisone shots?
Put plainly: you are trading real cartilage now for temporary relief that does not even last.
That is worth naming exactly because of how the offer usually feels. A cortisone shot looks like a cheap, low-stakes fix. It is quick, familiar, covered by insurance, and over in minutes. Nothing about the visit tells you that something lasting is being spent.
But cartilage does not renew the way comfort does. Relief comes and fades on a cycle. Cartilage does not come back on a cycle. The costs are lopsided, and the convenience of the shot hides that.
It is not a cure. It is a high-interest loan against your joint. The principal is drawn from something you cannot replace. The payments come due later, in a currency the person making the loan never has to collect.
Why do doctors keep recommending cortisone shots?
If the two-year data looks that bad, why is the shot still the standard next step?
The answer is built into the system. Repeated cortisone fits the model almost perfectly. It is cheap, quick, paid for, simple to do, and gives an effect you can feel before you leave the building. It wraps up a visit neatly. It makes a happy patient in the short term. The long-term cost lands years later, often in a different setting, under a different diagnosis. It gets blamed on the natural course of arthritis, not on anything that was injected.
That is not an accusation against any physician. It describes what a system built for volume and fast results will reliably produce. When the incentives, the visit length, the billing, and the patient’s instant experience all point at the same tool, that tool becomes the default. It stays the default no matter what the two-year data says. Changing that means changing the structure, not blaming the people inside it.
When does a cortisone shot make sense?
None of this makes cortisone wrong to use. That is an important point, and it should not get lost.
You can use a steroid as a rare, strategic bridge. Sometimes calming an inflammatory signal opens the window you need to do something else. It can help you get through rehab, get through a set period, or make a specific plan work. Used that way, with an end point and a purpose beyond itself, it is a reasonable tool.
What the evidence argues against is making it your destination. That means an open-ended arrangement with no set end, repeated every few months until the joint reaches the point where a different conversation begins.
The regenerative alternative starts from the opposite idea. It lines treatment up with how joints actually heal, not with how fast a signal can be silenced. That is slower and less instantly satisfying. It is also aimed at a different outcome.
The point is not that you must pick one. The point is to decide with your eyes open. Know what the two-year data shows. Know what is being spent. And know there is a question worth asking your physician before the next injection, not after it.
Frequently asked questions
Should I stop the cortisone injections I am currently receiving?
No — not on your own. Do not start, stop, or change any treatment without consulting your physician. Bring the trial findings described here to the physician managing your care, or seek a formal second evaluation. This page exists to inform that conversation, not to replace it.
Was I supposed to be told about the cartilage findings?
An informed choice requires knowing what the evidence shows, and many patients say it was never discussed. That gap comes more from how short a standard visit is, and how routine the shot has become, than from anyone’s intent. Either way, it is completely reasonable to raise it now.
Is there ever a good reason to get a cortisone shot?
Yes, as a rare, strategic bridge. Calming an inflammatory signal for a set period, with a purpose beyond the relief itself, is a valid use. The evidence argues against repeating it as an open-ended plan, not against the tool existing.
What does an approach aligned with how joints heal actually look like?
It targets the joint’s biology, not the pain signal the joint is sending. So it works on a longer timeline, and the tissue and the terrain around it must be evaluated first. Individual results vary, and not every patient is a candidate for the therapies described. What applies to your joint is decided by exam and imaging.
How long does relief from a cortisone shot last?
Not long enough to justify repeating it forever. Many patients notice the relief arriving on a shorter lease with each shot, fading and returning on a cycle. In the two-year placebo-controlled trial above, repeated cortisone gave no better pain relief at two years than saline. The short-term effect is real. The long-term comfort benefit did not show up.
Does cartilage grow back after repeated cortisone shots?
No. Cartilage does not renew the way comfort does. Relief comes and goes on a cycle. Cartilage does not come back on a cycle. That is why the trial finding matters. Repeated cortisone caused significantly more cartilage loss than saline, and that loss comes from something your joint cannot replace.
How many cortisone shots are too many?
The problem is less a count than a pattern. What the evidence argues against is repeating it as an open-ended plan: a shot every few months with no set end. A steroid works as a rare, strategic bridge. Use it for a set period, with a purpose beyond the relief itself, such as making rehab bearable. Ask your physician what the end point is before the next injection, not after it.
Key takeaways
- In a rigorous two-year placebo-controlled trial, repeated cortisone caused significantly more cartilage loss than saline.
- The same trial found no better pain relief at two years than saline. So there is no comfort benefit to offset the cartilage cost.
- The trade is real cartilage now for short-term relief that does not last. That makes it a loan against the joint, not a cure.
- The shot stays the default because it fits a short-visit, insurance-paid, volume-driven model. Not because the long-term evidence favors repeating it.
- A steroid can be a rare, strategic bridge. The argument is against accepting it as a destination.
This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Sources
- McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA, 2017. PubMed 28510679 · doi:10.1001/jama.2017.5283
- Zeng C, Lane NE, Hunter DJ, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage, 2019. PubMed 30703543 · doi:10.1016/j.joca.2019.01.007